Please assess the completion status of the following clinical trial:

Trial Title: ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Lung cancer patients who answer true to the following statements are eligible to join this clinical study.~* I have a confirmed diagnosis of locally advanced or metastatic non small cell lung cancer (Stage IIIb - IV)~* I have had 1st line anti-cancer therapy. Previous treatment with Avastin (bevacizumab) in first line NSCLC is allowed.~Exclusion Criteria:~Lung cancer patients who answer true to the following are NOT eligible to join this clinical study.~* I do not have non small cell lung cancer (NSCLC)~* I have received treatment with docetaxel (Taxotere). Prior treatment with paclitaxel is acceptable.~* I have received 2nd line anti-cancer therapy (For example, patients with previous 2nd line non small cell lung cancer (NSCLC) treatment with Tarceva (erlotinib, OSI-744), Alimta (pemetrexed) are not eligible)~* I have been treated with VEGFR-tyrosine kinase inhibitors (TKIs) (sunitinib, sorafenib, other VEGF TKIs). Previous treatment with Avastin (bevacizumab) in 1st line non small cell lung cancer is permitted.~* I have a history of uncontrolled irregular heartbeat~* I have a history of high blood pressure which has not been controlled with medication If you are unsure of the meaning of the inclusion and exclusion criteria above, please contact the call center number for help.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Docetaxel monotherapy
- 2 (Type: EXPERIMENTAL): Vandetanib + Docetaxel

Based on this trial design, predict the completion outcome and termination type (if applicable).